ArticleScientific reports2025
Determinants of treatment success and cost implications in MDR/RR-TB patients: a prospective cohort study in China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predictors of Treatment Outcomes Among HIV-Positive Patients with Drug-Resistant Tuberculosis in Rural Eastern Cape, South Africa: A Retrospective Cohort Study.International journal of environmental research and public health · 2026Article
- The impact of social protection interventions on treatment and socioeconomic outcomes of tuberculosis-affected people and households in low income, high burden settings: A systematic review and meta-analysis.PLOS global public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB) remains a critical global health threat. While novel regimens offer promise, the impact of socioeconomic determinants and clinical factors on treatment success is inadequately characterized, hindering targeted interventions. A prospective cohort study was conducted across 13 TB-designated hospitals in Jiangsu Province, China from 2021 to 2022. Binary logistic regression identified predictors of treatment success, with model performance assessed via Receiver Operating Characteristic (ROC) curves assessing predictive performance. The overall treatment success rate for patients with MDR/RR-TB was 67.38%, with the short-term regimen achieving a success rate of 74.4%, new long-term oral regimens at 66.7%, new long-term injectable regimens at 71.0%, traditional long-term regimens at 60.3%, though differences were not statistically significant (P = 0.454). Patients educated at the junior and senior high school levels (OR = 3.95, 95% CI: 1.70, 9.19, P = 0.001) and at the college level or above (OR = 3.13, 95% CI: 1.03, 9.51, P = 0.044) exhibited significantly higher success rates compared to those with primary school education or lower. Moreover, it underscores the irrelevance of cost to treatment outcomes. Additionally, urban workers (OR = 4.53, 95% CI: 1.22, 16.86, P = 0.024), urban residents (OR = 4.61, 95% CI: 1.25, 17.04, P = 0.022), and individuals covered by other medical insurance, including public medical insurance (OR = 8.82, 95% CI: 1.50, 51.76, P = 0.016), demonstrated higher treatment success rates compared to those without medical insurance. Conversely, hypokalemia (OR = 0.12, 95% CI: 0.02, 0.61, P = 0.010) was identified as a risk factor for successful treatment. Treatment costs demonstrated no significant association with outcomes (OR = 1.06, 95%CI: 0.96, 1.17, P = 0.284). Prioritizing health literacy programs, insurance expansion, and hypokalemia monitoring is essential for improving treatment success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.